RollingStone Co., Ltd. (KOSDAQ:214610)
South Korea · Delayed Price · Currency is KRW 2,290.00
-55.00 (-2.35%)
At close: Mar 23, 2026
RollingStone Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue Revenue Growth | 891.68 | 4,640 | 5,367 | 16,111 | 30,302 | 45,672 |
Revenue Growth | -89.26% | -13.55% | -66.69% | -46.83% | -33.65% | 1014.48% |
Gross Profit Gross Profit Growth | -977.35 | -6,020 | -6,971 | -578.73 | 14,704 | 20,864 |
Operating Income Operating Income Growth | -10,204 | -21,969 | -19,983 | -25,922 | -10,859 | 3,466 |
Net Income Net Income Growth | -21,074 | -30,849 | -25,774 | -38,893 | -10,575 | -5,776 |
Earnings Per Share EPS Growth | -1078.21 | -7073.32 | -10420.00 | -17712.59 | -4825.15 | -3300.46 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Biochemical Diagnosis Division Biochemical Diagnosis Division Growth | 2,062 | 2,916 | 3,223 | 2,066 | 3,059 | 4,953 |
Molecular Diagnosis Division Molecular Diagnosis Division Growth | 741.56 | 1,006 | 1,694 | 6,023 | 24,788 | 38,933 |
Immuno Diagnostic Division Immuno Diagnostic Division Growth | 289.59 | 462.86 | 413.86 | 8,023 | 2,455 | 1,786 |
Other Other Growth | -3,311 | 255.45 | 36.64 | - | - | - |
Total Total Growth | 891.68 | 4,640 | 5,367 | 16,111 | 30,302 | 45,672 |
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Investments Cash & Investments Growth | 11,970 | 13,773 | 22,638 | 13,995 | 35,965 | 24,133 |
Total Debt Total Debt Growth | 4,607 | 21,407 | 13,660 | 23,282 | 22,164 | 6,736 |
Net Cash (Debt) Net Cash Growth | 7,362 | -7,634 | 8,977 | -9,287 | 13,801 | 17,397 |
Net Cash Growth | - | - | - | - | -20.67% | - |
Net Cash Per Share Net Cash Per Share Growth | 376.42 | -1750.50 | 3627.78 | -4229.49 | 6296.86 | 9941.62 |
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Cash Flow Operating Cash Flow Growth | -11,809 | -10,696 | -11,359 | -14,006 | -8,600 | -18,679 |
Capital Expenditures CapEx Growth | -8,805 | -955.55 | -385.41 | -1,625 | -2,841 | -5,761 |
Free Cash Flow Free Cash Flow Growth | -20,614 | -11,652 | -11,744 | -15,631 | -11,441 | -24,440 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Gross Margin | -109.61% | -129.73% | -129.88% | -3.59% | 48.52% | 45.68% |
Operating Margin | -1144.32% | -473.46% | -372.30% | -160.89% | -35.83% | 7.59% |
Pretax Margin | -2189.40% | -632.21% | -480.82% | -241.64% | -34.98% | -12.67% |
Profit Margin | -2363.40% | -664.83% | -480.20% | -241.40% | -34.90% | -12.65% |
FCF Margin | -2311.80% | -251.10% | -218.81% | -97.02% | -37.76% | -53.51% |
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
PS Ratio | 21.51 | 13.12 | 15.03 | 5.45 | 5.50 | 4.47 |